Galapagos NV

(NASDAQ:GLPG)

Latest On Galapagos NV (GLPG):

Date/Time Type Description Signal Details
2023-05-06 09:51 ESTNewsGalapagos Stands Strong On Jyseleca Positive Clinical DataN/A
2023-05-05 21:26 ESTNewsGalapagos NV (GLPG) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 19:34 ESTNewsGalapagos GAAP EPS of €0.40, revenue of €178.9MN/A
2023-05-03 18:15 ESTNewsGalapagos Q1 2023 Earnings PreviewN/A
2023-05-03 05:16 ESTNewsGalapagos announces departure of COO and CFO Bart FiliusN/A
2023-03-30 21:01 ESTNewsGalapagos to transfer drug discovery and research activities in France to NovAliXN/A
2023-02-24 11:36 ESTNewsGalapagos NV (GLPG) Q4 2022 Earnings Call TranscriptN/A
2023-02-23 22:33 ESTNewsGalapagos reports FY 2022 results, sees further reduction of cash burn in FY 2023N/A
2023-02-11 10:09 ESTNewsGalapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy RatingN/A
2023-02-09 18:47 ESTNewsGalapagos stock dips as Jyseleca fails phase 3 trial as induction therapy in Crohn's disease, cancels plan for EU filingN/A
2023-02-08 02:22 ESTNewsGalapagos: Deeply Into Negative EV Territory, Exciting BD Optionality, BuyN/A
2022-12-31 07:11 ESTNewsGalapagos: Slow Transformation, But Led By An ExpertN/A
2022-11-07 11:28 ESTNewsGalapagos downgraded to market perform at Raymond James on unclear path forwardN/A
2022-11-03 19:29 ESTNewsGalapagos GAAP EPS of -€0.16, revenue of €410.2MN/A
2022-11-03 02:25 ESTNewsGalapagos Q3 2022 Earnings PreviewN/A
2022-10-10 20:03 ESTNewsGalapagos: Trading At Discount To Cash With A Fast-Growing Marketed ProductN/A
2022-10-03 19:25 ESTNewsEMA panel approves amending label for Galapagos' Jyseleca on testicular function effectsN/A
2022-09-09 14:41 ESTNewsGalapagos cut at Morgan Stanley on positive but slow transformationN/A
2022-08-06 18:23 ESTNewsGalapagos NV (GLPG) CEO Paul Stoffels on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 20:20 ESTNewsGalapagos GAAP EPS of -€0.49, revenue of €274MN/A
2022-07-25 21:27 ESTNewsGalapagos stock dips after Jefferies slashes rating citing challenges aheadN/A
2022-06-21 19:06 ESTNewsGalapagos to enter cell therapy space with acquisition of CellPoint and AboundBioN/A
2022-05-30 23:31 ESTNewsMorgan Stanley updates biotechs with negative enterprise values & 2022 catalystsN/A
2022-05-25 07:04 ESTNewsGalapagos to license drug targets for inflammatory bowel disease from Scipher MedicineN/A
2022-05-20 09:10 ESTNewsGalapagos: Can The Company Turn Around?N/A
2022-05-06 13:39 ESTNewsGalapagos GAAP EPS of -€0.20, revenue of €136.3MN/A
2022-05-06 13:39 ESTNewsGalapagos NV (GLPG) CEO Paul Stoffels on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-06 13:38 ESTNewsGalapagos NV 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-05 15:51 ESTNewsGalapagos Q1 2022 Earnings PreviewN/A
2022-03-28 07:24 ESTNewsGilead, Galapagos' Jyseleca gets approval in Japan for expanded use in ulcerative colitisN/A
2022-02-25 18:23 ESTNewsGalapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-25 01:06 ESTNewsGalapagos GAAP EPS of -€1.58, revenue of €484.85MN/A
2022-02-24 05:28 ESTNewsGalapagos Q4 2021 Earnings PreviewN/A
2022-02-22 14:27 ESTNewsGalapagos: A History Of Disruptive FailuresN/A
2022-01-28 00:18 ESTNewsGalapagos at a six-month high after naming former J&J science chief as CEON/A
2022-01-27 07:39 ESTNewsGalapagos creates 1M subscription rights; stock rises 9%N/A
2022-01-26 14:26 ESTNewsEinhorn's Greenlight discloses positions in Global Payments, Capri, Galapagos, ODP Corp.N/A
2022-01-19 05:53 ESTNewsGalapagos' Jyseleca wins UK marketing authorization for ulcerative colitisN/A
2022-01-09 00:57 ESTNewsBiogen, Galapagos and Ultragenyx among key biotech calls at Morgan Stanley for 2022N/A
2021-12-04 00:46 ESTNewsGalapagos announces increase in share capital with subscription right exercisesN/A
2021-12-02 09:17 ESTNewsGalapagos: The Investment Thesis Is More Appealing Than EverN/A
2021-11-15 16:53 ESTNewsGalapagos wins EU approval for Jyseleca for ulcerative colitisN/A
2021-11-08 23:33 ESTNewsGalapagos rises as analysts highlight a major catalyst aheadN/A
2021-11-05 17:29 ESTNewsGalapagos NV's (GLPG) CEO Onno van de Stolpe on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 20:49 ESTNewsGalapagos reports Q3 resultsN/A
2021-11-03 23:37 ESTNewsGalapagos Q3 2021 Earnings PreviewN/A
2021-10-04 18:03 ESTNewsGalapagos posts results from post-hoc analyses of filgotinib in ulcerative colitisN/A
2021-09-22 14:07 ESTNewsGalapagos' filgotinib wins positive CHMP opinion for treatment of ulcerative colitisN/A
2021-08-19 18:51 ESTNewsGalapagos lowered to equal weight at Barclays; doubts acquisition driven upsideN/A
2021-08-08 04:48 ESTNewsGalapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call TranscriptN/A

About Galapagos NV (GLPG):

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

See Advanced Chart

General

  • Name Galapagos NV
  • Symbol GLPG
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Fiscal Year EndDecember
  • IPO Date2005-05-06
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.glpg.com
View More

Valuation

  • Trailing PE 60.65
  • Price/Sales (Trailing 12 Mt.) 9.78
  • Price/Book (Most Recent Quarter) 1.69
  • Enterprise Value Revenue 1.18
  • Enterprise Value EBITDA 3.11
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Current Year EPS Estimate -$4.89
  • Next Year EPS Estimate -$4.50
  • Next Quarter EPS Estimate -$0.28
  • Profit Margin -58%
  • Return on Assets -2%
  • Return on Equity -11%
  • Earnings Per Share -$1.69
  • Revenue Per Share $0
  • Gross Profit 6.6 million
  • Quarterly Earnings Growth -77.6%
View More

Highlights

  • Market Capitalization 5.28 billion
  • Analyst Target Price $93.67
  • Book Value Per Share $25.49
View More

Share Statistics

  • Shares Outstanding 65.41 million
  • Shares Float 43.14 million
  • % Held by Insiders <1%
  • % Held by Institutions 11.77%
  • Shares Short 936943
  • Shares Short Prior Month 966729
  • Short Ratio 2.3
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 0.28
  • 52 Week High $233.14
  • 52 Week Low $79.59
  • 50 Day Moving Average 90.41
  • 200 Day Moving Average 114.01
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Galapagos NV (GLPG) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Galapagos NV (GLPG) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-18-$1.06-$1.5330.28%
2020-09-302020-11-05$131.82 million-$1.49-$0.99-51.08%
2020-06-302020-08-06$N/A-$2.10-$0.85-147.49%
2020-03-312020-05-07$N/A-$0.85-$0.862.01%
2019-12-312020-02-20$160.81 million-$2.34-$0.79-193.91%
2019-09-302019-10-24$701.86 million$7.05$3.29114.55%
2019-06-302019-07-25$76.28 million-$0.97-$1.2522.41%
2019-03-312019-04-25$45.88 million-$0.99-$1.022.59%
2018-12-312019-02-21$129.35 million$0.31-$0.90134.1%
2018-09-302018-10-24$119.48 million$0.32-$1.10129.08%
2018-06-302018-08-02$66.38 million-$0.49-$1.0051.42%
2018-03-312018-04-25$55.24 million-$0.89-$1.1119.74%
2017-12-312018-02-22$61.81 million-$0.73-$0.9120.04%
2017-09-302017-10-26$42.3 million-$0.84-$0.9310.37%
2017-06-302017-07-27$40.69 million-$0.86-$0.67-29.5%
2017-03-312017-04-27$42.65 million-$0.32-$0.5946.03%
2016-12-312017-02-23$86.89 million$1.05$0.10897.14%
2016-09-302016-10-27$19.3 million-$0.57-$0.6614.05%
2016-06-302016-07-28$36.92 million-$0.11-$0.2146.22%
2016-03-312016-04-28$16.88 million$0.89$1.30-31.2%
2015-12-312016-03-03$13.08 million-$1.69-$0.84-101.49%
2015-09-302015-11-13$11.52 million-$0.72$4.06-117.73%
2015-06-302015-08-06$19.68 million-$0.59-$0.35-68.57%

Galapagos NV (GLPG) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Galapagos NV (GLPG) Chart:

Galapagos NV (GLPG) News:

Below you will find a list of latest news for Galapagos NV (GLPG) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Galapagos NV (GLPG) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-10-1712.50CALL0 00TRUE00
2025-10-17150CALL0 00TRUE00
2025-10-1717.50CALL0 00TRUE00
2025-10-17200CALL0 00TRUE00
2025-10-1722.50CALL0 00TRUE00
2025-10-17258.2CALL0 55181.29TRUE00
2025-10-1727.56.62CALL0 10TRUE00
2025-10-17304CALL7 6070TRUE40
2025-10-1732.51.8CALL0 3894.69TRUE00
2025-10-17350.9CALL0 76166.9FALSE00
2025-10-1737.50.81CALL0 6361.28FALSE00
2025-10-17400.65CALL0 8393.87FALSE00
2025-10-1742.50.45CALL0 5443.83FALSE00
2025-10-17450CALL0 0478.08FALSE00
2025-10-1747.50CALL0 0508.99FALSE00
2025-10-17500CALL0 0537.18FALSE00
2025-10-1712.50PUT0 01330.41FALSE00
2025-10-17150PUT0 01119.26FALSE00
2025-10-1717.50PUT0 0955.15FALSE00
2025-10-17200PUT0 2820.23FALSE00
2025-10-1722.50PUT0 1704.81FALSE00
2025-10-17250.1PUT0 39602.96FALSE00
2025-10-1727.50.15PUT0 60510.59FALSE00
2025-10-17301.96PUT0 304424.56FALSE00
2025-10-1732.50.3PUT0 25055.69FALSE00
2025-10-17350PUT0 0117.9TRUE00
2025-10-1737.50PUT0 081.35TRUE00
2025-10-17400PUT0 0113.26TRUE00
2025-10-1742.50PUT0 0140.83TRUE00
2025-10-17450PUT0 0165.41TRUE00
2025-10-1747.50PUT0 0187.71TRUE00
2025-10-17500PUT0 0208.18TRUE00
2025-11-2117.50CALL0 00TRUE00
2025-11-21200CALL0 059.39TRUE00
2025-11-2122.50CALL0 061.57TRUE00
2025-11-21250CALL0 00TRUE00
2025-11-2127.50CALL0 031.07TRUE00
2025-11-21300CALL0 033.51TRUE00
2025-11-2132.50CALL0 034.12TRUE00
2025-11-21350CALL0 063.1FALSE00
2025-11-2137.52.05CALL0 1137.1FALSE00
2025-11-21400.9CALL0 2653.28FALSE00
2025-11-2142.50CALL0 0168.82FALSE00
2025-11-21450CALL0 0181.98FALSE00
2025-11-2147.50CALL0 0193.84FALSE00
2025-11-21500CALL0 0204.65FALSE00
2025-11-2117.50PUT0 0366.8FALSE00
2025-11-21200PUT0 0315.14FALSE00
2025-11-2122.50PUT0 0270.96FALSE00
2025-11-21250PUT0 0231.99FALSE00
2025-11-2127.50PUT0 0196.66FALSE00
2025-11-21300PUT0 0163.79FALSE00
2025-11-2132.50PUT0 0132.22FALSE00
2025-11-21350PUT0 046.65TRUE00
2025-11-2137.50PUT0 033.78TRUE00
2025-11-21400PUT0 046.68TRUE00
2025-11-2142.50PUT0 057.83TRUE00
2025-11-21450PUT0 067.79TRUE00
2025-11-2147.50PUT0 076.84TRUE00
2025-11-21500PUT0 085.17TRUE00
2026-01-1612.50CALL0 00TRUE00
2026-01-16150CALL0 00TRUE00
2026-01-1617.50CALL0 076.4TRUE00
2026-01-16200CALL0 049.22TRUE00
2026-01-1622.50CALL0 047.5TRUE00
2026-01-16250CALL0 035.47TRUE00
2026-01-1627.50CALL0 024.59TRUE00
2026-01-16302.95CALL0 1625.99TRUE00
2026-01-1632.56CALL0 4523.39TRUE00
2026-01-16353CALL0 18866.25FALSE00
2026-01-1637.52.5CALL0 553.01FALSE00
2026-01-16401.55CALL0 1299.17FALSE00
2026-01-1642.52.22CALL0 1108.84FALSE00
2026-01-16450CALL0 0117.44FALSE00
2026-01-1647.50CALL0 0125.19FALSE00
2026-01-16500CALL0 0132.25FALSE00
2026-01-1612.50PUT0 0333.53FALSE00
2026-01-16150PUT0 0280.77FALSE00
2026-01-1617.50PUT0 0239.81FALSE00
2026-01-16200PUT0 0206.17FALSE00
2026-01-1622.50PUT0 0177.42FALSE00
2026-01-16250PUT0 0152.07FALSE00
2026-01-1627.50PUT0 0129.11FALSE00
2026-01-16301.58PUT0 10107.77FALSE00
2026-01-1632.50PUT0 050.26FALSE00
2026-01-16350PUT0 034.57TRUE00
2026-01-1637.50PUT0 033.39TRUE00
2026-01-16408.25PUT0 133.94TRUE00
2026-01-1642.50PUT0 040.56TRUE00
2026-01-16450PUT0 047.42TRUE00
2026-01-1647.50PUT0 053.65TRUE00
2026-01-16500PUT0 059.38TRUE00
2026-04-1717.50CALL0 037.06TRUE00
2026-04-17200CALL0 038.64TRUE00
2026-04-1722.50CALL0 00TRUE00
2026-04-172512.5CALL0 229.83TRUE00
2026-04-1727.50CALL0 025.61TRUE00
2026-04-17300CALL0 026.72TRUE00
2026-04-1732.50CALL0 024.56TRUE00
2026-04-17353.6CALL0 238.5FALSE00
2026-04-1737.53CALL0 1360.04FALSE00
2026-04-17402.2CALL0 244.77FALSE00
2026-04-1742.50CALL0 077.19FALSE00
2026-04-17451.55CALL0 483.41FALSE00
2026-04-1747.50CALL0 083.8FALSE00
2026-04-17501.6CALL0 1394.13FALSE00
2026-04-1717.50PUT0 0173.69FALSE00
2026-04-17200PUT0 0149.47FALSE00
2026-04-1722.50PUT0 088.56FALSE00
2026-04-17250PUT0 0103.46FALSE00
2026-04-1727.50.5PUT0 8945.1FALSE00
2026-04-17301.5PUT0 2853.52FALSE00
2026-04-1732.52.1PUT0 2538.41FALSE00
2026-04-17350PUT0 032.67TRUE00
2026-04-1737.50PUT0 031.27TRUE00
2026-04-17400PUT0 032.6TRUE00
2026-04-1742.50PUT0 031.74TRUE00
2026-04-17450PUT0 036.98TRUE00
2026-04-1747.50PUT0 041.75TRUE00
2026-04-17500PUT0 046.14TRUE00

Latest GLPG Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST100$54.06
Jun 13, 2022 7:58 PM EST10$53.98
Jun 13, 2022 7:58 PM EST1$53.98
Jun 13, 2022 7:59 PM EST1$53.985
Jun 13, 2022 7:59 PM EST100$53.99

Galapagos NV (GLPG) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004215/0001171843-20-004215-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000090221920000071/0000902219-20-000071-index.htm
2019-07-17SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000110465919040709/0001104659-19-040709-index.htm
2019-07-23SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919041473/0001104659-19-041473-index.htm
2019-08-29SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919047927/0001104659-19-047927-index.htm
2019-11-01SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1421876/000110465919059005/0001104659-19-059005-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000110465920021860/0001104659-20-021860-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1421876/000114036120003311/0001140361-20-003311-index.htm
2019-05-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319003728/0001171843-19-003728-index.htm
2019-06-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319003920/0001171843-19-003920-index.htm
2019-06-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004030/0001171843-19-004030-index.htm
2019-06-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004093/0001171843-19-004093-index.htm
2019-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004317/0001171843-19-004317-index.htm
2019-07-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004585/0001171843-19-004585-index.htm
2019-07-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319004659/0001171843-19-004659-index.htm
2019-09-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319005832/0001171843-19-005832-index.htm
2019-09-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319005833/0001171843-19-005833-index.htm
2019-09-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006023/0001171843-19-006023-index.htm
2019-09-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006051/0001171843-19-006051-index.htm
2019-09-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006114/0001171843-19-006114-index.htm
2019-10-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006401/0001171843-19-006401-index.htm
2019-10-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006466/0001171843-19-006466-index.htm
2019-10-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006850/0001171843-19-006850-index.htm
2019-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319006892/0001171843-19-006892-index.htm
2019-11-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007092/0001171843-19-007092-index.htm
2019-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007260/0001171843-19-007260-index.htm
2019-11-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007410/0001171843-19-007410-index.htm
2019-11-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007516/0001171843-19-007516-index.htm
2019-11-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007642/0001171843-19-007642-index.htm
2019-11-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319007826/0001171843-19-007826-index.htm
2019-12-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319008012/0001171843-19-008012-index.htm
2019-12-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184319008255/0001171843-19-008255-index.htm
2020-01-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000139/0001171843-20-000139-index.htm
2020-01-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000140/0001171843-20-000140-index.htm
2020-01-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000174/0001171843-20-000174-index.htm
2020-01-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000237/0001171843-20-000237-index.htm
2020-01-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000469/0001171843-20-000469-index.htm
2020-01-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320000556/0001171843-20-000556-index.htm
2020-03-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320001794/0001171843-20-001794-index.htm
2020-04-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002640/0001171843-20-002640-index.htm
2020-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002674/0001171843-20-002674-index.htm
2020-04-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320002689/0001171843-20-002689-index.htm
2020-05-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320003977/0001171843-20-003977-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004053/0001171843-20-004053-index.htm
2020-06-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004164/0001171843-20-004164-index.htm
2020-06-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320004215/0001171843-20-004215-index.htm
2020-07-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005194/0001171843-20-005194-index.htm
2020-08-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005906/0001171843-20-005906-index.htm
2020-08-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320005998/0001171843-20-005998-index.htm
2020-08-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006087/0001171843-20-006087-index.htm
2020-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006405/0001171843-20-006405-index.htm
2020-09-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006525/0001171843-20-006525-index.htm
2020-09-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006651/0001171843-20-006651-index.htm
2020-09-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006681/0001171843-20-006681-index.htm
2020-09-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320006727/0001171843-20-006727-index.htm
2020-10-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007002/0001171843-20-007002-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007061/0001171843-20-007061-index.htm
2020-10-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007261/0001171843-20-007261-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007481/0001171843-20-007481-index.htm
2020-11-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000117184320007726/0001171843-20-007726-index.htm
2019-08-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519234109/0001193125-19-234109-index.htm
2019-09-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519250691/0001193125-19-250691-index.htm
2019-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519272244/0001193125-19-272244-index.htm
2019-10-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312519274853/0001193125-19-274853-index.htm
2020-03-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520088879/0001193125-20-088879-index.htm
2020-04-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520126328/0001193125-20-126328-index.htm
2020-05-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000119312520139028/0001193125-20-139028-index.htm
2020-10-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1421876/000119312520267249/0001193125-20-267249-index.htm
2019-07-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000155837019006344/0001558370-19-006344-index.htm
2020-03-2720-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1421876/000155837020003270/0001558370-20-003270-index.htm
2020-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1421876/000155837020009632/0001558370-20-009632-index.htm